Construction and preclinical evaluation of a 124 I-labelled bispecific antibody targeting PD-L1 and PD-L2.

Yuan YaoYanan RenXingguo HouPei WangJinyu ZhuSong LiuXiaokun MaTeli LiuZhi Yang Hua Zhu Nan Li

Published in: European journal of nuclear medicine and molecular imaging (2024)

I]I-NB12 may be a promising strategy for identifying cancer patients that can potentially benefit from ICI therapy.

Keyphrases